News & Research

MAXALT-MLT SUMMARY

MAXALT is indicated for the acute treatment of migraine attacks with or without aura in adults.

MAXALT is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of MAXALT have not been established for cluster headache, which is present in an older, predominantly male population.

Published Studies Related to Maxalt-Mlt (Rizatriptan)

Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders. [2011.05]OBJECTIVE: The study was carried out to assess the efficacy and tolerability of rizatriptan orally disintegrating tablet (ODT) for treating acute migraine in patients who are non-responders to sumatriptan. BACKGROUND: Many migraineurs report dissatisfaction with sumatriptan efficacy. It is unclear whether sumatriptan 100 mg non-responders will respond to other triptans... CONCLUSION: Rizatriptan 10-mg ODT was superior to placebo at providing two-hour pain relief and two-hour pain freedom in the treatment of acute migraine in those who do not respond to sumatriptan 100 mg. Rizatriptan was generally well tolerated in this population.

Clinical Trials Related to Maxalt-Mlt (Rizatriptan)

Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1) [Completed]
A study to assess the safety, tolerability, and single dose pharmacokinetics of a marketed
drug in pediatric subjects with migraines.
After completion of a portion of the study (Panels A and B), a regulatory agency issued an
amended request that the 12-17 year old age group studied should include a similar number of
male and female subjects. Therefore, the study was amended to add an additional panel of
subjects (Panel C) to ensure gender balance specifically in this age group.